Holen Sie sich die Stockscreener-App
578.43
1.76%
10.00
Handel nachbörslich:
576.00
-2.43
-0.42%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$568.43
Offen:
$564.61
24-Stunden-Volumen:
776.30K
Relative Volume:
1.48
Marktkapitalisierung:
$24.55B
Einnahmen:
$3.17B
Nettoeinkommen (Verlust:
$1.29B
KGV:
21.35
EPS:
27.0947
Netto-Cashflow:
$1.01B
1W Leistung:
+2.05%
1M Leistung:
+1.99%
6M Leistung:
+18.43%
1J Leistung:
+88.02%
1-Tages-Spanne:
$560.60
$578.80
1-Wochen-Bereich:
$555.25
$578.80
52-Wochen-Spanne:
$272.12
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
United Therapeutics Corporation (UTHR) Latest Stock News & Headlines - Yahoo Finance
United Therapeutics Corp at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares - Investing.com India
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares By Investing.com - Investing.com South Africa
United Therapeutics stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
United Therapeutics CEO Rothblatt sells $5.4m in common stock By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt sells $5.4m in common stock - Investing.com
UTHR Technical Analysis | Trend, Signals & Chart Patterns | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
United Therapeutics (UTHR) Remains a Key Holding for Renaissance Technologies - GuruFocus
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock - Investing.com Nigeria
United Therapeutics (UTHR) Reports TETON Study Results on Nebuli - GuruFocus
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock By Investing.com - Investing.com South Africa
United Therapeutics’ Tyvaso meets primary endpoint in IPF trial - Investing.com
Inhaled Tyvaso preserves lung function, cuts IPF risks in trial - Stock Titan
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics (UTHR) Reports Positive Ralinepag Results in Pulmonary Hypertension Study - GuruFocus
Baidu, Brady And 3 Stocks To Watch Heading Into Monday - Benzinga
Experimental PAH pill ralinepag cuts worsening risk 55% in Phase 3 - Stock Titan
Leuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock (US9113631090): FDA clears first UHeart xenotransplantation trial - AD HOC NEWS
United Therapeutics Corporation $UTHR Stock Position Decreased by Thrivent Financial for Lutherans - MarketBeat
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call - Yahoo Finance
United Therapeutics Corporation Announces Fda Clearance to Proceed with Uheart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics stock (US9113631090): fresh data push at ATS 2026 keeps pipeline in focus - AD HOC NEWS
United Therapeutics (UTHR) Receives FDA Approval for UHeart Clin - GuruFocus
FDA clears first human trial of pig-derived transplant heart - Stock Titan
United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares - MarketBeat
UTHRUnited Therapeutics Corp Stock Price and Quote - Finviz
Varda Space and United Therapeutics to test drugs in space microgravity - Новости GxP
Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock By Investing.com - Investing.com Canada
Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock - Investing.com
Pacer Advisors Inc. Trims Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Ameritas Advisory Services LLC Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
Varda Space, United Therapeutics to test lung drugs in orbit - qz.com
United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
United Therapeutics director Mesa Nilda sells $150,139 in stock By Investing.com - Investing.com Australia
Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics director Mesa Nilda sells $150,139 in stock - Investing.com
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EDGEMOND JAMES | CFO AND TREASURER |
May 21 '26 |
Sale |
564.11 |
10,000 |
5,641,130 |
18,876 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 21 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 21 '26 |
Sale |
564.11 |
9,500 |
5,359,011 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 20 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
May 20 '26 |
Sale |
565.98 |
9,500 |
5,376,814 |
40,513 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
May 21 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
May 21 '26 |
Sale |
562.82 |
8,300 |
4,671,399 |
45,172 |
2.34%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):